DARE (Daré Bioscience) FY2025 Earnings & Business Update

Market Cap: ~$23.8M Stage: Early commercial / clinical Focus: Women's health platform

The Numbers

• Cash: $24.7M as of 12/31/25

• Working capital: $3.4M (tight)

• R&D: $5.5M (down from $14.3M, offset by $16.4M in non-dilutive grant funding)

• SG&A: $8.8M

• ATM dilution 2025: $20.8M raised

• Non-dilutive funding 2025: $19.4M (Gates $13.6M, ARPA-H $4.5M, NIH $1.3M)

Nearly dollar-for-dollar grant funding vs dilutive raises. That's the story here. Gates Foundation and ARPA-H don't write checks to nobodies.

Pipeline

Five programs, two launching commercially Q2 2026 through a 503B compounding pathway (no FDA approval needed, faster to revenue):

• DARE to PLAY (sildenafil cream): Topical for female arousal. Prescriptions live in all 50 states via telehealth. Dispensing and revenue expected Q2 2026. 20M women unmet need. Zero FDA-approved competitors. Also pursuing full NDA

• Flora Sync LF5 (vaginal probiotic): 100-person clinical trial data. Revenue expected Q2 2026

• DARE to RECLAIM (hormone therapy ring): Bio-identical estradiol/progesterone. $2.5-4.5B compounded HRT market. Revenue targeted early 2027

• Ovaprene (Phase 3): Non-hormonal monthly contraceptive. Enrollment completing 2026. DSMB said continue without modification. Topline data 2027

• DARE-HPV (Phase 2): First therapeutic for high-risk HPV. IND cleared Feb 2026. Phase 2 starting 2026. Fully funded by $10M ARPA-H contract

Founder Review

Sabrina Martucci Johnson, CEO. Built this company over 10 years solely around women's health. Not a pivot. Medicine Maker's Power List, Fierce Pharma Most Influential. Attracted Gates Foundation and ARPA-H backing. No prior exits. The 503B dual-path strategy is smart but 10 years at $23.8M cap without an FDA approval is a long runway with no touchdown.

Catalysts

• Q2 2026: DARE to PLAY first revenue

• Q2 2026: Flora Sync LF5 first revenue

• 2026: Ovaprene Phase 3 enrollment complete

• 2026: DARE-HPV Phase 2 start

• Early 2027: DARE to RECLAIM launch

• 2027: Ovaprene topline data

M&A Score: 58/100. $23.8M cap is dirt cheap. Five programs, Gates/ARPA-H backing, platform value. But 503B compounded products aren't the clean FDA-approved assets acquirers want. Cash is tight with more dilution coming. CEO messaging is "build to grow" not "build to sell."

Growth Score: 55/100. Two revenue streams launching Q2 2026. Real platform breadth across five indications. Non-dilutive funding is impressive. But $3.4M working capital is razor thin, ATM is active, and 503B revenue ramps slowly through DTC telehealth. The inflection is Q2 revenue. If prescriptions ramp, this reprices. If they trickle, more dilution follows.

Tag: M&A Target.